Fig. 1. Number of events, incidence rates per 10,000, and adjusted rate ratios (aRR) with 95% CIs for medically attended acute adverse events occurring 1–7, 1–21, or 1–42 days after mRNA monovalent coronavirus disease 2019 (COVID-19) booster vaccination in pregnant people at eight Vaccine Safety Datalink sites, September 23, 2021–June 30, 2022. Rates of medically attended acute adverse events in pregnant people receiving a COVID-19 booster vaccine in the 28 days before pregnancy start date or during pregnancy were compared with those of an unexposed pregnant cohort who did not receive a COVID-19 vaccine in the 28 days before pregnancy start date or during the matched exposure window during pregnancy. Outcomes evaluated but for which there were no cases in the COVID-19 booster–vaccinated or unexposed groups include acute disseminated encephalomyelitis, cerebral venous sinus thrombosis, Guillain-Barré syndrome, Stevens-Johnson syndrome or toxic epidermal necrolysis, thrombosis with thrombocytopenia syndrome, transverse myelitis, and thrombotic thrombocytopenic purpura.

DeSilva. COVID-19 Booster Adverse Events in Pregnancy. Obstet Gynecol 2023.